LabGenomics announced on the 21st that it has launched the next-generation sequencing (NGS) test for all cancer types, ‘OTD Solid PLUS’.
OTD Solid PLUS analyzes 517 genes to provide information necessary for the treatment of all solid tumors, using Thermo Fisher Scientific’s high-precision cancer test NGS panel, ‘Oncomine Comprehensive Assay Plus’. This panel was utilized in the large-scale clinical trial ‘NCI-MATCH’ conducted by the U.S. National Cancer Institute (NCI) involving more than 6,000 tumor patients to provide personalized treatment. It was also used in SCRUM-Japan, a clinical trial conducted on over 10,000 tumor patients in Japan.
OTD Solid PLUS requires less than half the specimen compared to the hybrid capture method. It provides various results necessary for tumor treatment, including mutations occurring in 517 single-gene biomarkers related to tumors, as well as multi-gene biomarkers such as tumor mutational burden (TMB), homologous recombination deficiency (HRD), and microsatellite instability (MSI).
LabGenomics stated, “Previously, only gene mutations could be identified, but the results we provide include multi-biomarkers, which can serve as the basis for prescribing PARP inhibitors, immune checkpoint inhibitors, and targeted anticancer drugs, which have recently gained attention as treatment options. Through this, patients will be able to receive diverse and effective treatment options.”
They added, “While standalone HRD tests for prescribing PARP inhibitors previously cost several million won, OTD Solid PLUS can determine HRD positivity or negativity through NGS testing alone, which will help reduce cost burdens. The European Society for Medical Oncology (ESMO) recommends HRD testing for ovarian cancer patients, so market growth benefits are also expected,” emphasizing the point.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
